Federal preemption and its impact on state restrictions limiting access to mifepristone and abortion care
Session Overview The FDA’s Risk Evaluation and Mitigation Strategy (REMS) for mifepristone allows patients to obtain the drug without an in-person visit to a clinician. Ongoing federal litigation has challenged...